A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
We haven't written up this one. CNBC World has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.